J&J’s eyes are on $100 billion

Introduction

Johnson & Johnson is a well-known company, recognised for its MedTech innovations and effective, innovative pharmaceuticals. Since 1886, the company has contributed to and advanced the journey in the vast healthcare sector with greater confidence and dedication, poised to thrive in this advanced era. The company’s history begins with three brothers who used to sell sterile surgical dressings, which later made a space in the top healthcare provider list. Their brands speaks volume about their hardship and commitment throughout the healthcare sector.

Announcement

According to the sources, Johnson & Johnson (J&J) healthcare giant, is aiming for $100 billion in revenue. The company set its target of revenue profit since last year with $94.2 billion, continuing into this year, the expectation heights are peaking more confidently. J&J are on the same lane as Eli Lilly, giving tough competition to Lilly; the U.S. pharma market is witnessing crazy, unpredictable scenarios due to the dedication of these two companies.

J&J have many other areas where revenue can be earned, but the company, being a perfectionist, will smartly bring all its portfolios and robust solutions under revaluation and introduce precision back again, learning the healthcare market’s current status.

J&J’s profit areas

In 2025, J&J experienced 6% growth in its sales, following this profit, the results showed the winning potential of its best-selling drugs globally. Stelara, an autoimmune drug, is a star of the company but still earned less profit after losing patent protection. Despite this drop, J&J’s CFO Joseph Wolk is still positive, noting that the legacy such as dermatitis treatment Tremfaya earned around $3.6 billion in 2024 and showed growth in 2025 with earnings of $5.2 billion.

Alongside Spravato, a depression treatment, also showed a profit from $1.1 billion to $1.7 billion. The analyst at Jefferies also pointed out J&J’s esketamine spray as a potential seller in the healthcare market. The psychedelic-based treatments, such as Spravato, in different indications, consisting of post-traumatic stress and anxiety condition can also stand out in the regulatory ecosystem.

Apart from this company’s oncology portfolio also rapidly gaining profit with its heavy sales for CAR T treatment Carvykti and anti-tumor antibody Darzalex. Wolk claimed that the tariffs actually affected our medical technologies branch. We hope tariffs stress will be less this year. J&J’s CEO, Joaquin Duato, said, “Last year was a successful year for us. We placed Stelara in the rearview mirror.”